U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

NAFLD1(FLD1)

MedGen UID:
413307
Concept ID:
C2750440
Finding
Synonyms: Fatty liver disease, nonalcoholic 1; FATTY LIVER DISEASE, SUSCEPTIBILITY TO, 1; FLD1; PNPLA3-Related Susceptibility to Nonalchoholic Fatty Liver Disease
 
Monarch Initiative: MONDO:0021105
OMIM®: 613282

Definition

The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver disease, FLD), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. Genetic Heterogeneity of Fatty Liver Disease Another form of fatty liver disease (FLD2; 613387) has been associated with variation in the APOC3 gene (107720). [from OMIM]

Additional description

From MedlinePlus Genetics
Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged.

Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding.

NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer).  https://medlineplus.gov/genetics/condition/non-alcoholic-fatty-liver-disease

Clinical features

From HPO
Hepatic steatosis
MedGen UID:
398225
Concept ID:
C2711227
Disease or Syndrome
Steatosis is a term used to denote lipid accumulation within hepatocytes.

Recent clinical studies

Diagnosis

Mozaffari S, Aliari M, Emamgholipour S, Hosseini H, Amirkiasar PR, Zare M, Katsiki N, Panahi G, Sahebkar A
J Diabetes Complications 2024 Aug;38(8):108780. Epub 2024 Jun 6 doi: 10.1016/j.jdiacomp.2024.108780. PMID: 38968867

Therapy

Mozaffari S, Aliari M, Emamgholipour S, Hosseini H, Amirkiasar PR, Zare M, Katsiki N, Panahi G, Sahebkar A
J Diabetes Complications 2024 Aug;38(8):108780. Epub 2024 Jun 6 doi: 10.1016/j.jdiacomp.2024.108780. PMID: 38968867

Clinical prediction guides

Mozaffari S, Aliari M, Emamgholipour S, Hosseini H, Amirkiasar PR, Zare M, Katsiki N, Panahi G, Sahebkar A
J Diabetes Complications 2024 Aug;38(8):108780. Epub 2024 Jun 6 doi: 10.1016/j.jdiacomp.2024.108780. PMID: 38968867

Recent systematic reviews

Mozaffari S, Aliari M, Emamgholipour S, Hosseini H, Amirkiasar PR, Zare M, Katsiki N, Panahi G, Sahebkar A
J Diabetes Complications 2024 Aug;38(8):108780. Epub 2024 Jun 6 doi: 10.1016/j.jdiacomp.2024.108780. PMID: 38968867

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...